Navigation Links
'Paradigm shift' in how physicians treat peripheral artery disease
Date:10/5/2010

A balloon angioplasty device that sucks up dangerous plaque debris could trigger a "paradigm shift" in how physicians treat peripheral artery disease, researchers write in the current issue of Endovascular Today.

"We will see a shift in how we treat lesions," write Dr. Robert Dieter of Loyola University Health System and Dr. Aravinda Nanjundappa of West Virginia University.

In two clinical trials totaling 123 patients, the device had a success rate of 97 percent to 99 percent and consistently outperformed filter devices typically used to capture debris particles, Dieter and Nanjundappa write.

The Food and Drug Administration has approved the device, Proteus, made by Angioslide, for angioplasties that treat peripheral artery disease (PAD) in the legs. PAD is caused by clogged arteries that restrict blood flow to the legs. Symptoms include painful cramping in the hips, thighs or calves when walking, climbing stairs or exercising. Advanced PAD can cause gangrene or even lead to limb loss.

A balloon angioplasty is among the standard treatments for PAD. A physician inserts a catheter in an artery and guides it to the blockage, then opens the artery by inflating a balloon at the tip of the catheter. The physician typically deploys a stent to keep the artery open.

Inflating the balloon can knock loose particles of plaque, which travel down the leg. A large particle can block blood flow, a condition called distal embolization. In the most severe cases, distal embolizations can require leg amputation or even be fatal.

Until now, some physicians have used a filter device to prevent debris from escaping. However, the filter can damage the artery, and can be difficult to deploy. Moreover the FDA has not approved filter devices for use in leg arteries. Using filters for PAD procedures, although routine, must be done "off label."

The new device that Dieter used opens the artery just like a standard angioplasty balloon. After the artery is opened, the physician deflates the balloon. The negative pressure sucks up the debris, which is trapped inside as the balloon retracts.

"This is a much more simple and elegant approach than filter devices," said Dieter, an interventional cardiologist and vascular specialist.

Dieter is an assistant professor in the Department of Medicine, Division of Cardiology at Loyola University Chicago Stritch School of Medicine and Director of Vascular Medicine and Peripheral Vascular Interventions at Edward Hines VA Hospital. Dieter has used the device on patients at Loyola and Hines.

His first Loyola patient was Patricia Durkin of Oak Forest, Il. Before the procedure, the top of the iliac artery that supplies blood to her left leg was 90 percent blocked. "If I walked in the mall, I had to stop every few minutes," she said. "It made my leg feel heavy. It got to the point where I didn't want to walk any distance."

The procedure restored normal blood flow. "I don't have that heavy feeling anymore," Durkin said.

Other interventional cardiologists at Loyola also plan to use the device, said Dr. John Lopez, director of Interventional Cardiology Research and professor in the Department of Medicine, Division of Cardiology.

"At Loyola, interventional cardiology is very progressive, and at the forefront of technology for the treatment of PAD," Lopez said.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. New global report launched by the International AIDS Society recommends a new paradigm for treating injecting drug users: Seek, test, treat and retain
2. Researchers suggest new paradigm for breast cancer screening
3. Staggered radiologist work shifts improve patient care, study suggests
4. Shape-shifting robot plane offers safer alternative for maritime rescue
5. Penn study sheds light on how the brain shifts between sleep/awake states under anesthesia
6. Lexington Health Care Chooses OnShift for Nurse Scheduling and Employee Communications in all Facilities
7. The best and worst work schedules: Shift start times can impact sleep and alertness
8. Caffeine Helps Shift Workers Avoid Mistakes
9. New Finding Could Mark Shift in Alzheimers Research
10. Hospital Cost Shifting Adds to Auto Injury Claim Costs
11. Getting heavier, younger: U-M study shows generational shift in obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: